GlaxoSmithKline Pulls Tykerb sNDA Ahead Of FDA Panel Review
This article was originally published in The Pink Sheet Daily
Executive Summary
The sponsor withdrew the application for combination use of lapatinib with Roche’s Herceptin in breast cancer less than two weeks before a scheduled advisory committee review, because of questions from FDA “that could not be addressed with the data currently available.” Those questions may have been driven by concerns about the clinical meaningfulness of a four-week median progression-free survival benefit and other efficacy issues.
You may also be interested in...
After ALTTO: I-SPY Will Hold More Clues About pCR Surrogate Endpoint
The pathological complete response surrogate marker has been hailed as the key to getting drugs to market faster with small studies, but came under attack at ASCO with the failed ALTTO breast cancer trial. Co-lead I-SPY investigator Laura Esserman takes a critical look at ALTTO and explains why the jury is still out on pCR; story features an audio clip of Esserman’s interview with “The Pink Sheet.”
GSK’s Oncology Expansion Heavily Dependent On Dabrafenib, Trametinib
GlaxoSmithKline announced NDA filings for BRAF inhibitor dabrafenib and MEK inhibitor trametinib in metastatic melanoma on Aug. 3. The two compounds represent one-quarter of the company’s novel oncology agents in clinical development, according to the most recent pipeline update.
GSK’s Oncology Expansion Heavily Dependent On Dabrafenib, Trametinib
GlaxoSmithKline announced NDA filings for BRAF inhibitor dabrafenib and MEK inhibitor trametinib in metastatic melanoma on Aug. 3. The two compounds represent one-quarter of the company’s novel oncology agents in clinical development, according to the most recent pipeline update.